DCF Advisers LLC Invests $616,000 in Savara Inc. $SVRA

DCF Advisers LLC bought a new position in shares of Savara Inc. (NASDAQ:SVRA) in the second quarter, according to the company in its most recent filing with the SEC. The firm bought 100,000 shares of the company’s stock, valued at approximately $616,000.

Several other institutional investors have also recently added to or reduced their stakes in the company. Swedbank AB grew its stake in Savara by 54.5% during the fourth quarter. Swedbank AB now owns 850,000 shares of the company’s stock worth $5,126,000 after buying an additional 300,000 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Savara by 96.5% during the first quarter. Renaissance Technologies LLC now owns 652,672 shares of the company’s stock worth $3,564,000 after buying an additional 320,572 shares in the last quarter. F m Investments LLC raised its stake in shares of Savara by 56.5% in the fourth quarter. F m Investments LLC now owns 678,813 shares of the company’s stock valued at $4,093,000 after acquiring an additional 245,100 shares during the last quarter. Nan Fung Trinity HK Ltd. bought a new position in shares of Savara in the fourth quarter valued at approximately $10,182,000. Finally, Orbimed Advisors LLC acquired a new position in shares of Savara in the 1st quarter worth approximately $3,467,000. 87.93% of the stock is owned by institutional investors.

Savara Stock Up 3.9%

Shares of NASDAQ:SVRA opened at $5.58 on Thursday. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. The firm has a market cap of $1.15 billion, a P/E ratio of -9.62 and a beta of 0.29. Savara Inc. has a 12 month low of $2.92 and a 12 month high of $7.01. The company’s 50-day moving average price is $5.68 and its two-hundred day moving average price is $5.47.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). As a group, research analysts forecast that Savara Inc. will post -0.62 EPS for the current fiscal year.

Analyst Ratings Changes

SVRA has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. Oppenheimer assumed coverage on Savara in a research report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price objective for the company. Finally, Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Savara currently has a consensus rating of “Moderate Buy” and an average target price of $10.14.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.